{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:13:39Z","timestamp":1793286819687,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"British Columbia Provincial Health Services Authority"},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"crossref","award":["356069-09"],"award-info":[{"award-number":["356069-09"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"crossref","award":["355912-11"],"award-info":[{"award-number":["355912-11"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CIHR Banting"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.pnpbp.2013.10.006","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T04:02:01Z","timestamp":1381896121000},"page":"170-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine"],"prefix":"10.1016","volume":"48","author":[{"given":"Heidi N.","family":"Boyda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.Y.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.10.006_bb0005","first-page":"332","article-title":"Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats","volume":"49","author":"Adeneye","year":"2011","journal-title":"Indian J Exp Biol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0015","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.lfs.2006.06.016","article-title":"Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice","volume":"79","author":"Arulmozhi","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2008.06.105","article-title":"The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063","volume":"592","author":"Assie","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0028-1085438","article-title":"Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial","volume":"42","author":"Baptista","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.0953-816X.2004.03457.x","article-title":"Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia","volume":"20","author":"Barr","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0045","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/j.1460-9568.2008.06233.x","article-title":"Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins","volume":"27","author":"Barr","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0055","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"Boyda","year":"2012","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0065","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0070","doi-asserted-by":"crossref","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine","volume":"8","author":"Boyda","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pnpbp.2013.10.006_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1037\/a0031228","article-title":"Antipsychotic polypharmacy increases metabolic dysregulation in female rats","volume":"21","author":"Boyda","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0080","first-page":"1","article-title":"Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats","volume":"19","author":"Boyda","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0085","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1464-5491.2010.03098.x","article-title":"Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target","volume":"27","author":"Boyle","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","article-title":"Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14week, double-blind, parallel group, placebo-controlled study","volume":"113","author":"Carrizo","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0095","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1517\/13543780903143753","article-title":"Rosiglitazone maleate+metformin hydrochloride extend: review of an emerging compound","volume":"18","author":"Cheng","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/156652413804486287","article-title":"First phase insulin secretion and type 2 diabetes","volume":"13","author":"Cheng","year":"2013","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0120","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.clinthera.2007.09.011","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","article-title":"The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats","volume":"194","author":"Fell","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0130","doi-asserted-by":"crossref","first-page":"e43244","DOI":"10.1371\/journal.pone.0043244","article-title":"Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance","volume":"7","author":"Girault","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0135","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1592\/phco.31.12.44S","article-title":"Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus","volume":"31","author":"Goldman-Levine","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2009.12.015","article-title":"Does long-term metformin treatment increase cardiac lipoprotein lipase?","volume":"60","author":"Hauton","year":"2011","journal-title":"Metabolism"},{"issue":"Suppl. 12","key":"10.1016\/j.pnpbp.2013.10.006_bb0145","first-page":"18","article-title":"Weight gain with atypical antipsychotics: evidence and insights","volume":"68","author":"Henderson","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00023210-200721090-00001","article-title":"Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia","volume":"21","author":"Honer","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.10.006_bb0160","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00213-011-2397-y","article-title":"Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat","volume":"219","author":"Jassim","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0165","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.2353\/ajpath.2010.090370","article-title":"Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage","volume":"176","author":"Kiss","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0170","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1517\/14656566.2012.738196","article-title":"Combination of glibenclamide\u2013metformin HCl for the treatment of type 2 diabetes mellitus","volume":"13","author":"Lamos","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0185","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0190","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40291-012-0002-7","article-title":"Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data","volume":"16","author":"Mannino","year":"2012","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10401230500464737","article-title":"Focus on lower risk of tardive dyskinesia with atypical antipsychotics","volume":"18","author":"Nasrallah","year":"2006","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2013.10.006_bb0205","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"Suppl. 4","key":"10.1016\/j.pnpbp.2013.10.006_bb0210","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042018812458697","article-title":"Interventions for the metabolic syndrome in schizophrenia: a review","volume":"3","author":"Papanastasiou","year":"2012","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0220","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000285780","article-title":"Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats","volume":"61","author":"Park","year":"2010","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0225","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0269881109348167","article-title":"Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them","volume":"24","author":"Park","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0230","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1447-0349.2011.00747.x","article-title":"Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics","volume":"20","author":"Park","year":"2011","journal-title":"Int J Ment Health Nurs"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0235","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/070674371205701202","article-title":"A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents","volume":"57","author":"Patten","year":"2012","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0240","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/0269881107080215","article-title":"Schizophrenia, antipsychotics and metabolic disease","volume":"21","author":"Reynolds","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0255","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/11209750-000000000-00000","article-title":"Exenatide extended-release: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0260","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.10.006_bb0270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/13813455.2011.576681","article-title":"Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat","volume":"117","author":"Smith","year":"2011","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0275","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00125-011-2311-5","article-title":"Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status","volume":"54","author":"Stephenne","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0280","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(85)90403-9","article-title":"The sulphonylurea receptor may be an ATP-sensitive potassium channel","volume":"2","author":"Sturgess","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0285","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","author":"Tse","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2008.01309.x","article-title":"Schizophrenia and physical health problems","author":"von Hausswolff-Juhlin","year":"2009","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0295","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1038\/npp.2008.9","article-title":"Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats","volume":"33","author":"Wallingford","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0300","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1210\/endo.142.3.8037","article-title":"Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues","volume":"142","author":"Way","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0305","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain\u2014far from the clinic?","volume":"116","author":"Weston-Green","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.10.006_bb0310","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav Brain Res"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613002224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613002224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T18:04:50Z","timestamp":1564509890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584613002224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":62,"alternative-id":["S0278584613002224"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.10.006","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}